Cargando…

Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival

BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiencke, John K., Koestler, Devin C., Salas, Lucas A., Wiemels, Joseph L., Roy, Ritu P., Hansen, Helen M., Rice, Terri, McCoy, Lucie S., Bracci, Paige M., Molinaro, Annette M., Kelsey, Karl T., Wrensch, Margaret R., Christensen, Brock C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288996/
https://www.ncbi.nlm.nih.gov/pubmed/28184256
http://dx.doi.org/10.1186/s13148-017-0316-8
_version_ 1782504434769592320
author Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Wiemels, Joseph L.
Roy, Ritu P.
Hansen, Helen M.
Rice, Terri
McCoy, Lucie S.
Bracci, Paige M.
Molinaro, Annette M.
Kelsey, Karl T.
Wrensch, Margaret R.
Christensen, Brock C.
author_facet Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Wiemels, Joseph L.
Roy, Ritu P.
Hansen, Helen M.
Rice, Terri
McCoy, Lucie S.
Bracci, Paige M.
Molinaro, Annette M.
Kelsey, Karl T.
Wrensch, Margaret R.
Christensen, Brock C.
author_sort Wiencke, John K.
collection PubMed
description BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors. We first estimated the proportions of leukocyte subtypes in samples using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. Then, we calculated the neutrophil to lymphocyte ratio (NLR) using methylation-derived cell composition estimates (mdNLR). The NLR is considered an indicator of immunosuppressive cells in cancer patients. RESULTS: Elevated mdNLR scores were observed in glioma patients compared to mdNLR values of published controls. Significantly decreased survival times were associated with mdNLR ≥ 4.0 in Cox proportional hazards models adjusted for age, gender, tumor grade, and molecular subtype (HR 2.02, 95% CI, 1.11–3.69). We also identified five myeloid-related CpGs that were highly correlated with the mdNLR (adjusted R (2) ≥ 0.80). Each of the five myeloid CpG loci was associated with survival when adjusted for the above covariates and offer a simplified approach for utilizing fresh or archived peripheral blood samples for interrogating a very small number of methylation markers to estimate myeloid immune influences in glioma survival. CONCLUSIONS: The mdNLR (based on DNA methylation) is a novel candidate methylation biomarker that represents immunosuppressive myeloid cells within the blood of glioma patients with potential application in clinical trials and future epidemiologic studies of glioma risk and survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0316-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5288996
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52889962017-02-09 Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival Wiencke, John K. Koestler, Devin C. Salas, Lucas A. Wiemels, Joseph L. Roy, Ritu P. Hansen, Helen M. Rice, Terri McCoy, Lucie S. Bracci, Paige M. Molinaro, Annette M. Kelsey, Karl T. Wrensch, Margaret R. Christensen, Brock C. Clin Epigenetics Research BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors. We first estimated the proportions of leukocyte subtypes in samples using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. Then, we calculated the neutrophil to lymphocyte ratio (NLR) using methylation-derived cell composition estimates (mdNLR). The NLR is considered an indicator of immunosuppressive cells in cancer patients. RESULTS: Elevated mdNLR scores were observed in glioma patients compared to mdNLR values of published controls. Significantly decreased survival times were associated with mdNLR ≥ 4.0 in Cox proportional hazards models adjusted for age, gender, tumor grade, and molecular subtype (HR 2.02, 95% CI, 1.11–3.69). We also identified five myeloid-related CpGs that were highly correlated with the mdNLR (adjusted R (2) ≥ 0.80). Each of the five myeloid CpG loci was associated with survival when adjusted for the above covariates and offer a simplified approach for utilizing fresh or archived peripheral blood samples for interrogating a very small number of methylation markers to estimate myeloid immune influences in glioma survival. CONCLUSIONS: The mdNLR (based on DNA methylation) is a novel candidate methylation biomarker that represents immunosuppressive myeloid cells within the blood of glioma patients with potential application in clinical trials and future epidemiologic studies of glioma risk and survival. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0316-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-02 /pmc/articles/PMC5288996/ /pubmed/28184256 http://dx.doi.org/10.1186/s13148-017-0316-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wiencke, John K.
Koestler, Devin C.
Salas, Lucas A.
Wiemels, Joseph L.
Roy, Ritu P.
Hansen, Helen M.
Rice, Terri
McCoy, Lucie S.
Bracci, Paige M.
Molinaro, Annette M.
Kelsey, Karl T.
Wrensch, Margaret R.
Christensen, Brock C.
Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title_full Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title_fullStr Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title_full_unstemmed Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title_short Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival
title_sort immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (nlr) in glioma survival
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288996/
https://www.ncbi.nlm.nih.gov/pubmed/28184256
http://dx.doi.org/10.1186/s13148-017-0316-8
work_keys_str_mv AT wienckejohnk immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT koestlerdevinc immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT salaslucasa immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT wiemelsjosephl immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT royritup immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT hansenhelenm immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT riceterri immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT mccoylucies immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT braccipaigem immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT molinaroannettem immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT kelseykarlt immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT wrenschmargaretr immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival
AT christensenbrockc immunomethylomicapproachtoexplorethebloodneutrophillymphocyterationlringliomasurvival